DaltonTx launches its drug discovery platform, Dalton, and announces Sygnature Discovery collaboration

• Dalton is a drug discovery platform integrating agentic AI, human expertise, and experimental data into one continuous learning engine.
• Announces collaboration with Sygnature Discovery, a leading integrated drug discovery contract research organisation (CRO), as a client.

A powerful self-learning platform

Dalton is designed to help drug discovery teams learn faster from every decision they make. The platform links molecules, assays, models, experimental outcomes, project context and human decisions into a single learning system, capturing not only what happened, but also why a particular path was chosen. Over time, this builds organisational memory across discovery programmes, helping teams understand which approaches worked, which didn't, and how they can make better decisions in the future.

Dalton helps teams discover new small molecules and biologics by supporting every step of the design-make-test-learn cycle. It integrates experimental data, predictive models, physics-based methods and AI agents into conversational workflows. Scientists can use Dalton to plan analyses, orchestrate computational tools, compare different modelling approaches, update models as new data is generated, and surface suggestions on what to do next. This makes advanced computational methods easier for medicinal chemistry teams to use, while freeing up expert computational scientists from routine tasks so they can focus on more complex scientific challenges.

Sygnature Discovery welcomed to the Dalton platform

Alongside the drug discovery platform launch, DaltonTx announces its collaboration with Sygnature Discovery. This brings Dalton into Sygnature Discovery's existing computational and medicinal chemistry toolkit alongside proprietary and third-party technologies including SygDesign, BullFrog AI and Iktos. By combining multiple complementary AI platforms, Sygnature Discovery aims to support faster, more informed decision-making across discovery programmes.

"The next phase of AI in drug discovery is about impact. We believe that the organisations capturing the most value from AI will be those that connect their teams, tools and data into systems that improve real-world discovery decisions. Our Dalton drug discovery platform unifies data, models, and experimental results to capture what worked, what failed and why, with full context, so judgement compounds over time. We are proud to be working with such a respected industry partner as Sygnature Discovery, and it is a great endorsement of the tangible outcomes that Dalton can translate into measurable value."

— Dr. Garry Pairaudeau, CEO and Co-Founder, DaltonTx

As part of the collaboration, Sygnature Discovery is conducting a retrospective evaluation using a legacy oncology programme focused on a small molecule clinical candidate now in Phase I development. The analysis is assessing whether the platform could have enabled the team to reach candidate selection more efficiently through improved decision-making and reduced synthesis burden.

"AI in drug discovery continues to evolve rapidly, but we believe the future lies in combining the power of machine learning with the expertise and intuition of experienced scientists. We are excited to be working with DaltonTx and see how they can help scientists make better-informed decisions earlier in the discovery process, so that we can reduce the number of compounds synthesised and tested, shorten DMTA cycles and accelerate progression toward candidate selection."

— Simon Hirst, CEO, Sygnature Discovery

The collaboration also addresses growing industry concerns surrounding proprietary data use in AI-enabled environments. Sygnature Discovery confirmed that customer data and AI models are compartmentalised on a per-programme basis to ensure customer information is not used to train models supporting other projects.

Sygnature Discovery intends to extend validation of the Dalton platform into live customer programmes as opportunities arise.